Cartesian Therapeutics, Inc. (RNAC)
NASDAQ: RNAC · Real-Time Price · USD
7.54
+0.33 (4.58%)
May 29, 2026, 4:00 PM EDT - Market closed
Cartesian Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1.78 | 2.8 | 38.91 | 26 | 110.78 | 85.08 | |
Revenue Growth (YoY) | -94.81% | -92.81% | 49.64% | -76.53% | 30.21% | 412.61% |
Gross Profit | 1.78 | 2.8 | 38.91 | 26 | 110.78 | 85.08 |
Selling, General & Admin | 30.27 | 31.47 | 30.13 | 40.45 | 23.86 | 20.94 |
Research & Development | 62.82 | 58.03 | 45.11 | 71.26 | 72.38 | 68.74 |
Other Operating Expenses | - | 56.7 | 7.58 | 0.71 | - | - |
Total Operating Expenses | 93.09 | 146.2 | 82.81 | 112.42 | 96.24 | 89.67 |
Operating Income | -148.02 | -143.41 | -43.9 | -86.42 | 14.54 | -4.6 |
Interest Income | 5.59 | 6.58 | 7.39 | 4.96 | 2.07 | 0.04 |
Interest Expense | - | - | - | -2.83 | -3.03 | -2.84 |
Other Non-Operating Income (Expense) | -18.54 | -2.67 | -40.63 | -154.43 | 21.19 | -2.32 |
Total Non-Operating Income (Expense) | -12.95 | 3.91 | -33.24 | -152.29 | 20.23 | -5.12 |
Pretax Income | -160.97 | -139.5 | -77.14 | -238.71 | 34.77 | -9.72 |
Provision for Income Taxes | - | -9.19 | 0.29 | -19 | -0.61 | 15.97 |
Net Income | 13.26 | -130.3 | -77.42 | -219.71 | 35.38 | -25.69 |
Net Income Attributable to Preferred Dividends | 2.63 | - | - | - | - | - |
Net Income to Common | 13.26 | -130.3 | -77.42 | -219.71 | 35.38 | -25.69 |
Net Income Growth | 37.70% | - | - | - | - | - |
Shares Outstanding (Basic) | 26 | 26 | 17 | 145 | 145 | 114 |
Shares Outstanding (Diluted) | 26 | 26 | 17 | 146 | 146 | 114 |
Shares Change (YoY) | 15.84% | 49.63% | -88.10% | - | 27.59% | 3289.12% |
EPS (Basic) | -5.90 | -5.02 | -4.48 | -49.76 | 0.24 | -0.22 |
EPS (Diluted) | -5.91 | -5.02 | -4.49 | -49.76 | 0.10 | -0.22 |
Shares Outstanding | 28.54 | 26.01 | 25.77 | 5.4 | 5.1 | 4.12 |
Free Cash Flow | -77.37 | -79.4 | -32.77 | -51.37 | -32.83 | -61.47 |
Free Cash Flow Per Share | -2.94 | -3.06 | -1.89 | -0.35 | -0.23 | -0.54 |
Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
Operating Margin | -8338.87% | -5127.10% | -112.81% | -332.32% | 13.12% | -5.40% |
Profit Margin | -8550.65% | -4658.63% | -198.97% | -844.91% | 31.94% | -30.19% |
FCF Margin | -4359.10% | -2838.58% | -84.21% | -197.53% | -29.64% | -72.25% |
EBITDA | -145.6 | -140.45 | -42.75 | -85.57 | 15.83 | -3.35 |
EBITDA Margin | -8202.65% | -5021.31% | -109.85% | -329.08% | 14.29% | -3.93% |
EBIT | -148.02 | -143.41 | -43.9 | -86.42 | 14.54 | -4.6 |
EBIT Margin | -8338.87% | -5127.10% | -112.81% | -332.32% | 13.12% | -5.40% |
Effective Tax Rate | - | 6.59% | -0.37% | 7.96% | -1.75% | -164.24% |